TOKYO-METROPOLITAN
With the Olympic Games just around the corner, Tokyo Governor Koike Yuriko sent a video message to the world's media inviting them to the Tokyo Media Center (TMC) provided by the Tokyo Metropolitan Government. TMC offers services not only for members of the press coming to Tokyo but also those working from their home countries, a great opportunity to cover the Games and the City online no matter how far away. Registration is required for full use of member services. Do not miss the opportunity to receive regular full online updates about what’s happening in Tokyo during the Games!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005509/en/
Find the video invitation form Koike Yuriko, the Governor of Tokyo at https://tokyo.mediacenter.jp/about/
Register Now!
| 1) | Access TMC’s registration page at https://tokyo.mediacenter.jp/?modal=register |
|
| 2) | Submit your name and email for Account Registration. |
|
| 3) | Register your ID and proof of employment with the Accreditation Application at https://tokyo.mediacenter.jp/login/ |
Benefits of TMC Online Service
1) |
TMC Web will be your home for various information during the Games, including photos, videos, data regarding Tokyo and more. |
|
2) |
TMC Newsletters will update you twice a day with what’s happening in Tokyo during the Games. |
|
3) |
TMC Briefings will live-stream daily briefings from the Tokyo Metropolitan Government. You can cast questions to the officials. They are scheduled from 12:30 pm to 1:00 pm, Japan Standard Time (JST), from July 23 to August 8 and from August 24 to September 5, 2021. |
|
4) |
TMC Talks will video-stream daily live presentations and recorded messages by Governor Koike and/or global leaders from various fields such as sports, culture and urban development. The main theme will be the future of Tokyo. You can cast questions to speakers via online tools. More details about TMC Talks will be announced soon. They are scheduled from 2:00 pm to 2:40 pm, JST, from July 21 to August 8 and from August 23 to September 5, 2021. |
|
5) |
TMC Online Concierge will answer your questions and provide consultations about Tokyo-related coverage and photography. It will be available between 8:00 am and 10:00 pm, JST, from July 21 to August 8 and from August 23 to September 5, 2021. |
We are looking forward to serving you soon!
About the Tokyo Media Center (TMC)
The Tokyo Media Center (TMC) has been set up by the Tokyo Metropolitan Government to serve as a media coverage base for domestic and international media during the Olympic and Paralympic Games Tokyo 2020. TMC provides information related to the host city Tokyo as well as the Tokyo 2020 Games. It is totally separate from the Main Press Centre (MPC) and International Broadcast Centre (IBC), which are operated by the Tokyo 2020 Organising Committee.
Website
URL: https://tokyo.mediacenter.jp/
Facilities
Date and Time of Opening: |
|
Wednesday, July 21, 2021 to Monday, August 9, 8:00 am to 10:00 pm, JST |
|
Monday, August 23, 2021 to Sunday, September 5, 8:00 am to 10:00 pm, JST |
|
* A pre-opening is scheduled on Monday, July 19 and Tuesday, July 20. The details will be announced separately. |
|
Access: |
Tokyo Sports Square, 2nd and 3rd Floor (address: Marunouchi 3-8-3, Chiyoda-ku, Tokyo) |
1 minute walk from JR Yurakucho Station and Tokyo Metro Yurakucho Station |
|
Services: |
Workspace and lounge |
Approximately 120 seats available to create a work environment for journalists. |
|
A drink corner offering refreshments will also be provided. |
|
Information Desk |
|
Staff will respond to inquiries regarding facilities usage. Upon first entrance, guests will receive a media kit which includes complimentary Tokyo-related giveaways. |
|
Japan Showcase |
|
The Japan National Tourism Organization (JNTO) will have booths to promote Japan’s various regions and traditional culture. |
|
Japanese Liquors Booth |
|
The National Tax Agency (NTA) will have a booth to introduce Japanese liquors. |
|
Internet Connection |
|
Wi-fi available for use by registered members. |
|
* Detailed information such as COVID-19 countermeasures and how to enter the facilities will be periodically updated on the TMC website and TMC Briefings. |
|
TOKYO UPDATES
Tokyo Metropolitan Government (TMG) launched a new media platform to show the world the ever-changing face of Tokyo now and the future in May 2021. This platform features content such as articles which focus on the attractions of Tokyo and the people who live, study, and work in the city. Please be sure to check it out.
URL: https://www.tokyoupdates.metro.tokyo.lg.jp/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005509/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom